Pacific Biosciences of California, Inc. (PACB) stock
Close on Nov 11, 2026Market cap $649.64MP/E –Yield 0.00%
Pacific Biosciences of California, Inc. grew revenue 4.4% to $161.39M over the twelve months to Sep 30, 2026. Free cash flow was -$143.40M. At the latest close the market valued the company at $649.64M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $649.64M
- P/E ratio
- –
- Price to sales
- 4.03
- Price to book
- –
- Dividend yield
- 0.00%
- Free cash flow yield
- -22.07%
Fundamentals
- Revenue
- $161.39M
- Net income
- -$131.23M
- EPS, diluted
- -$0.42
- Free cash flow
- -$143.40M
- Book value per share
- -$0.20
- Diluted shares
- 311M
Trading
- Next earnings
- Feb 11, 2027 (estimated, after the close)
- Previous close
- $2.24
- Open
- $2.29
- Day's range
- $2.07 – $2.35
- Volume
- 10,693,900
- Average volume (20 days)
- 12,738,633
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 2.20
- 52-week range
- $1.07 – $3.44
- RSI (14 days)
- 46.1
- Volatility (1 year)
- 93.8%
- Relative volume
- 0.99×
- WACC
- 15.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PACB | S&P 500 | Difference | PACB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.3% | -2.4% | −7.9 pts | ||
| 3 months | +83.3% | -1.2% | +84.5 pts | ||
| Year to date | +11.8% | +12.3% | −0.5 pts | ||
| 1 year | +12.4% | +12.4% | −0.1 pts | ||
| 3 years | -67.9% | +78.8% | −146.8 pts | -31.6% | +21.4% |
| 5 years | -92.3% | +75.2% | −167.4 pts | -40.0% | +11.9% |
| 10 years | -73.7% | +311.1% | −384.8 pts | -12.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pacific Biosciences of California filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Pacific Biosciences of California
Laboratory Analytical Instruments
PacBio designs, manufactures, and sells genomic sequencing systems, microchips, and reagents built on its proprietary Single-Molecule Real-Time sequencing technology. Its products, which include Revio, Vega, and Sequel instruments alongside SMRT Cells and specialized assay kits, enable high-accuracy long-read sequencing of DNA and RNA. Researchers deploy these tools across rare disease research, human germline analysis, oncology, infectious disease surveillance, and plant and animal biology. The company supplies academic and governmental institutions, commercial laboratories, clinical research facilities, hospitals, agricultural enterprises, and biopharmaceutical organizations.
Company profile, executives and historyPacific Biosciences of California stock: common questions
What is Pacific Biosciences of California's stock price?
PACB closed at $2.09 on Nov 11, 2026, down 6.70% on the day. Over the past 52 weeks it traded between $1.07 and $3.44.
What is Pacific Biosciences of California's market cap?
Pacific Biosciences of California was worth $649.64M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PACB's P/E ratio?
Pacific Biosciences of California lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.42), so it has no meaningful P/E ratio.
How much revenue does Pacific Biosciences of California make?
Pacific Biosciences of California reported revenue of $161.39M for the twelve months to Sep 30, 2026, up 4.4% from a year earlier.
Does Pacific Biosciences of California pay a dividend?
No. Pacific Biosciences of California has not paid a cash dividend over the last twelve months.
When does Pacific Biosciences of California report earnings next?
Pacific Biosciences of California is expected to report Q4 FY2026 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PACB stock performed over the past year?
Including dividends, PACB returned +12.4% over the past year, against +12.4% for the S&P 500.
How many PACB shares are sold short?
54M shares were sold short at the latest FINRA report, 18.05% of the float, or 4.1 days of average trading volume.
Who are Pacific Biosciences of California's competitors?
Companies most similar to Pacific Biosciences of California by business, industry and size include QTRX, CTKB, TXG, HBIO, BNGO.
See a number that looks wrong?